CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...
News-Medical.Net4d
Alzheimer's-modifying drug lecanemab's effectiveness may vary between genders
Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...
Latest Alzheimer's drug shown less effective in females than males
Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...
UN Environment Programme4d
This data platform charts the health of nearly every freshwater body on Earth. Here’s what it reveals
The Freshwater Ecosystems Explorer offers what experts call an unprecedented look at the world’s lakes, rivers and wetlands, ...
Barron's10d
Starbucks Corp.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Decoding Biogen's Options Activity: What's the Big Picture?
Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...
Detroit News14d
Unions ask court to stop Musk group from accessing Social Security data of millions of Americans
Washington – A group of labor unions are asking a federal court for an emergency order to stop Elon Musk 's Department of Government Efficiency from accessing the sensitive Social Security data ...
AOL14d
How a new FDA-approved drug can — and can’t — help people with Alzheimer’s
So, what’s really going on? In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company ...
Wall Street Journal15d
Week Ahead for FX, Bonds: U.S. Inflation Data, Bank of Canada Decision Due
U.S. inflation data for February will be the highlight among economic data as investors continue to follow the back-and-forth of U.S. President Trump’s announcements on tariffs. A rate decision ...
precisionmedicineonline16d
NICE Still Not Recommending Leqembi, Kisunla for Alzheimer's in Updated Draft Guidance
The independent committee last year determined that Leqembi and Kisunla showed too little benefit to justify their cost to the National Health Service. Committee members had requested additional data ...
BioSpace16d
Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval
The U.K.’s National Institute for Health and Care Excellence on Thursday again denied to recommend Biogen and Eisai’s Alzheimer’s disease therapy Leqembi, noting that its clinical benefits do not ...
alzheimersnewstoday16d
Menopause, synapse health may interact to raise Alzheimer’s risk
The decision follows a supplemental application from Eisai, which is codeveloping Leqembi with Biogen, based on the modeling of data from the Phase… ...